Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
GLP-1 drugs and other constraints in Kroger's pharmacies are crimping profits
01:31pm, Thursday, 20'th Jun 2024
Grocery-store chain Kroger Co. on Thursday reported better-than-expected first-quarter results, helped in part by more enthusiasm from wealthier shoppers, but executives warned that difficulties in th
Eli Lilly's Stock Surge Driven by GLP-1 Demand
07:04am, Thursday, 20'th Jun 2024
Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
09:00am, Tuesday, 18'th Jun 2024
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a glo
Hims & Hers: The Undervalued Gem Poised For Growth
03:05am, Tuesday, 18'th Jun 2024
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already star
Looking at Next Gen of Weight Loss: Tema ETFs CEO
02:46pm, Monday, 17'th Jun 2024
Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
09:00am, Monday, 17'th Jun 2024
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp u
GLP-1 weight-loss drugs: Analyst discusses what investors should know
02:28pm, Friday, 14'th Jun 2024
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter join
Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts
07:28pm, Thursday, 13'th Jun 2024
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today ann
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
10:16am, Wednesday, 12'th Jun 2024
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain aft
Structure Therapeutics CEO on GLP drugs
06:37pm, Tuesday, 11'th Jun 2024
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to discuss the weight loss drug boom and the company's recent data finidngs in its own drug.
The Vitamin Shoppe CEO on GLP-1 drugs
11:42am, Tuesday, 11'th Jun 2024
The Vitamin Shoppe CEO Lee Wright joins 'Squawk on the Street' to discuss what the chief executive has learned about GLP-1 drugs, if science says GLP-1 users should supplement their diet with proteins
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
09:00am, Wednesday, 05'th Jun 2024
Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug deliver
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
07:42am, Monday, 03'rd Jun 2024
Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand an
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p
